Patents Assigned to Health Corporation
-
Patent number: 7087009Abstract: A valve for a bladder control device including an elongate housing having a valve seat disposed therein. A stopper is also disposed within the housing and is moveable between a first position in which the stopper engages the valve seat and a second position wherein the stopper is moved distally of the valve seat. A tension spring can be connected to the stopper to biases the stopper toward the valve seat. A lumen is defined through the housing having a first portion disposed distally of the valve seat having a diameter approximately equal to a diameter of the stopper. A second portion of the lumen disposed distally of the first portion has a greater diameter than the first portion of the lumen. Yet a third portion of the lumen disposed distally of the second portion has a diameter less than that of the first portion.Type: GrantFiled: July 6, 2005Date of Patent: August 8, 2006Assignee: Feelsure Health CorporationInventor: Valery Migachyov
-
Patent number: 7078512Abstract: The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4.Type: GrantFiled: April 30, 1999Date of Patent: July 18, 2006Assignees: Schering-Plough Animal Health Corporation, The Texas A & M University SystemInventors: Ellen W. Collisson, InSoo Choi, Barbara J. Winslow, Mark D. Cochran
-
Patent number: 7041670Abstract: The present invention relates to novel florfenicol compounds having the chemical structure: wherein the compounds are useful for the treatment and/or prevention of bacterial infections in a broad range of patients such as, without limitation, birds, fish, shellfish and mammals.Type: GrantFiled: April 8, 2003Date of Patent: May 9, 2006Assignee: Schering-Plough Animal Health CorporationInventors: Constantine G. Boojamra, Lee S. Chong, Scott J. Hecker, Tomasz W. Glinka, Dale E. Shuster
-
Publication number: 20050281737Abstract: A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal when the potential of explosive liquid oxygen is eliminated. The radioactive diagnostic radiopharmaceutical requires no further cold or refrigerated storage, including with respect to shipping, subsequent to stabilization.Type: ApplicationFiled: October 22, 2004Publication date: December 22, 2005Applicant: ANAZAO HEALTH CORPORATIONInventors: John Kuperus, Robert McKenzie, Brooke Schumm
-
Publication number: 20050209532Abstract: Disclosed is a method for testing a modified specimen such as a dried blood spot, plasma or serum specimen, for an analyte of interest, such as cholesterol. In accordance with the disclosed subject matter, the level of the analyte of interest in the medium from which the modified specimen was obtained (e.g., from a patient's blood) is determined based on the level of an analyte in a solution formed from the modified specimen and on the level of at least one normalizing analyte. The analyte and normalizing analyte each may be an ion, compound, biochemical entity, or property of the specimen. Also disclosed are a fluid collector and a fluid collection device.Type: ApplicationFiled: November 5, 2004Publication date: September 22, 2005Applicant: Home Access Health CorporationInventors: Michael Wandell, IIia Vinogradov, Barbara Godsey, Troy Bervig
-
Patent number: 6926665Abstract: A valve for a bladder control device including an elongate housing having a valve seat disposed therein. A stopper is also disposed within the housing and is moveable between a first position in which the stopper engages the valve seat and a second position wherein the stopper is moved distally of the valve seat. A tension spring can be connected to the stopper to biases the stopper toward the valve seat. A lumen is defined through the housing having a first portion disposed distally of the valve seat having a diameter approximately equal to a diameter of the stopper. A second portion of the lumen disposed distally of the first portion has a greater diameter than the first portion of the lumen. Yet a third portion of the lumen disposed distally of the second portion has a diameter less than that of the first portion.Type: GrantFiled: September 19, 2003Date of Patent: August 9, 2005Assignee: Feelsure Health CorporationInventor: Valery Migachyov
-
Publication number: 20050130310Abstract: Disclosed is a method for testing a modified specimen such as a dried blood spot, plasma or serum specimen, for an analyte of interest, such as cholesterol. In accordance with the disclosed subject matter, the level of the analyte of interest in the medium from which the modified specimen was obtained (e.g., from a patient's blood) is determined based on the level of an analyte in a solution formed from the modified specimen and on the level of at least one normalizing analyte. The analyte and normalizing analyte each may be an ion, compound, biochemical entity, or property of the specimen. Also disclosed are a fluid collector and a fluid collection device.Type: ApplicationFiled: November 12, 2003Publication date: June 16, 2005Applicant: Home Access Health CorporationInventors: Michael Wandell, Ilia Vinogradov, Barbara Godsey
-
Publication number: 20050095281Abstract: The present invention provides liposomal formulations comprising a lipid vesicle and at least one single chain lipid active agent. In addition, the present invention provides methods for using the same for preventing an infection in a mammal.Type: ApplicationFiled: March 12, 2004Publication date: May 5, 2005Applicants: OPTIME Therapeutics, Inc., Megee-Womens Health CorporationInventors: Hans Hofland, Lisa Rohan
-
Publication number: 20040242546Abstract: Novel formulations containing a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol, and methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease.Type: ApplicationFiled: May 28, 2004Publication date: December 2, 2004Applicant: SCHERING-PLOUGH ANIMAL HEALTH CORPORATIONInventors: Keith A. Freehauf, Allan Weingarten, Robert D. Simmons, Kanwal Jit Varma
-
Patent number: 6790867Abstract: Novel formulations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, with a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol are disclosed. Methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease and swine respiratory disease, are also disclosed.Type: GrantFiled: January 24, 2003Date of Patent: September 14, 2004Assignee: Schering-Plough Animal Health CorporationInventors: Raul E. Kohan, Kanwal J. Varma, Robert D. Simmons, Abu Huq, Keith A. Freehauf
-
Publication number: 20040092894Abstract: Apparatus, methods and kits for simultaneous delivery of a fluid or other substance to two or more breast milk ducts are provided. The fluid can be delivered for a variety of purposes including lavage of the ducts and administering an agent for therapeutic, prophylactic, or diagnostic purposes.Type: ApplicationFiled: June 27, 2003Publication date: May 13, 2004Applicant: Cytyc Health CorporationInventors: David Hung, Xuanmin He
-
Publication number: 20040091423Abstract: The invention is to methods for identifying asymptomatic patients who have a likelihood of benefiting from administration of an estrogen activity modulator for risk reduction or therapeutic treatment of breast cancer, methods for reducing risk or therapeutically treating these asymptomatic patients, and methods for monitoring the treatments.Type: ApplicationFiled: June 30, 2003Publication date: May 13, 2004Applicants: Cytyc Health Corporation, WINDY HILL TECHNOLOGY, INC. A Delaware CorporationInventors: David Hung, Susan Love
-
Patent number: 6712816Abstract: Methods, systems, and kits for treating breast tissue rely on transferring energy to or from cells lining an individual breast duct. Energy can be introduced into the breast duct, e.g., by filling the duct with an electrically conductive medium and applying radiofrequency energy to the medium. Other energy forms could also be used, such as light, ultrasound, radiation, microwave energy, heat, cold, direct current, and the like. By treating individual breast ducts, cancerous and pre-cancerous conditions originating in the duct can be effectively treated.Type: GrantFiled: May 15, 2002Date of Patent: March 30, 2004Assignee: Cytyc Health CorporationInventors: David Hung, Chris Ken, Julian Nikolchev, Susan Love, Shawn O'Leary
-
Publication number: 20040054300Abstract: Differentiating breast ducts for cancer risk status is a key element in a procedure to screen women for breast cancer. The 6 to 9 breast ducts on the human breast can be differentiated to identify those of higher risk for cancer. The higher risk ducts merit access and analysis of the ductal fluid and monitoring and/or treatment.Type: ApplicationFiled: August 19, 2003Publication date: March 18, 2004Applicants: Cytyc Health Corporation, PRO DUCT HEALTH, INC. A Delaware CorporationInventors: David Hung, Susan Love
-
Publication number: 20040038281Abstract: A sample for diagnosis of breast cancer can be prepared by isolating a ductal fluid sample from one duct of a breast of a patient. The isolated ductal fluid is not mixed with ductal fluid from any other duct of the breast. Generally the target duct is not spontaneously discharging. The isolated ductal fluid sample can be examined to determine the presence or absence of a marker associated with cancer or pre-cancer. An isolated ductal fluid sample not mixed with ductal fluid from any other duct of the breast permits identification of the duct which is diseased and provides increased sensitivity for existing diagnostic and analytic techniques.Type: ApplicationFiled: August 13, 2003Publication date: February 26, 2004Applicant: Cytyc Health CorporationInventor: David Hung
-
Publication number: 20040030248Abstract: The present invention relates to an apparatus and method for administering a radioactive tracer dye and an inhibitor compound into a breast duct of the breast and imaging the breast for breast lesions. The radioactive tracer dye may be Tc-99m sestamibi and the inhibitor compound may inhibit a P-glycoprotein pump in tumor cells. When the inhibitor compound inhibits the P-glycoprotein pump in tumor cells, the radioactive tracer dye may effectively accumulate in tumor cells and improve the sensitivity of nuclear imaging of breast lesions.Type: ApplicationFiled: March 19, 2003Publication date: February 12, 2004Applicant: Cytyc Health CorporationInventor: David Hung
-
Publication number: 20040029202Abstract: The invention is to methods for screening women for breast cancer and precancer by determining a level of an estrogen-related marker. The invention further provides methods of treating such patients identified as having one or more abnormal ductal epithelial cells and an estrogen-related marker. The invention provides methods for screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT. The invention provides methods of treating peri-, menopausal or postmenopausal women for both cancer risk reduction and menopausal symptoms (or other conditions related to lowered systemic estrogen levels). The invention also provides kits for the screening, monitoring, and treating methods described.Type: ApplicationFiled: August 11, 2003Publication date: February 12, 2004Applicant: Cytyc Health CorporationInventors: Susan Love, David Hung, Hui Cen
-
Publication number: 20040030264Abstract: The present invention relates to an apparatus and method for collecting and analyzing a biological specimen such as ductal fluid from a mammary gland duct. The biological specimen is contacted with a solid phase and cell markers that may be indicative of breast cancer or other lesions may be identified. Early diagnosis of breast cancer may be achieved as well as therapeutic or prognostic factors may be identified.Type: ApplicationFiled: March 19, 2003Publication date: February 12, 2004Applicant: Cytyc Health CorporationInventor: David Hung
-
Patent number: 6689070Abstract: The invention provides methods, devices and systems for collecting breast ductal fluid comprising cellular material and other useful markers for analysis. The methods typically comprise access of at least one breast duct and collecting materials from that duct separate from all other ducts in the breast. The devices comprise ductal access devices that provide the opportunity to collect fluid from a single duct separate from all the other ducts in the breast. The systems employ the methods and devices that used together provide systems for analysis of a breast condition in a patient specific to accessed breast ducts. The methods, devices and systems are particularly useful for identification of breast precancer or cancer in within the patient.Type: GrantFiled: March 29, 2002Date of Patent: February 10, 2004Assignee: Cytyc Health CorporationInventors: David Hung, Philip M. Olsen, Daniel R. Kurz
-
Publication number: 20040023912Abstract: The present invention relates to an apparatus and method for administering diagnostic and therapeutic agents into a breast duct. A thymidine kinase vector may be administered into a breast duct in conjunction with an acycloguanidine compound for enhanced imaging on PET scanning of the breast to detect breast lesions. The thymidine kinase phosphoraylates the acycloguanidine compound to enhance visibility of lesions on PET scan. An acyclic nucleoside compound may be administered into the breast duct to form phosphorylated adducts that phosphorylate DNA and kill thymidine kinase expressing cancer cells.Type: ApplicationFiled: March 17, 2003Publication date: February 5, 2004Applicant: Cytyc Health CorporationInventor: David Hung